November’s molecule, the Chugai/Lilly GLP-1R agonist LY3502970, is a highly potent and selective, oral, biased partial agonist of the GLP-1R GPCR. GLP-1R agonists have been approved for many years now to treat Type II diabetes mellitus, due to their ability to stimulate insulin secretion in pancreatic beta-cells. [...]
< 1 minute read
May 9, 2023
LY3502970
oral non-peptide GLP-1R GPCR partial agonist in Ph. I for Type 2 diabetes, HV study complete from cell-based screen and opt. PNAS Nov. 11, 2020 Chugai, Shizuoka, JP / Eli Lilly, Indianapolis, IN